OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Neurodegeneration is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
LRP1: a novel receptor for the transmission of pathological α-Synuclein	258
Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases	227
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	153
Regulation of cortical hyperexcitability in amyotrophic lateral sclerosis: focusing on glial mechanisms	148
The informed road map to prevention of Alzheimer Disease: A call to arms	148
Mitochondrial CISD1/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1/parkin models	142
Tau interactome and RNA binding proteins in neurodegenerative diseases	132
Fluid biomarkers for amyotrophic lateral sclerosis: a review	130
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	126
The TGFβ/Notch axis facilitates Müller cell-to-epithelial transition to ultimately form a chronic glial scar	122
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	120
A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy	119
A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer’s disease patients from controls	115
Pharmacological rescue of cognitive function in a mouse model of chemobrain	114
Regulation of the hippocampal translatome by Apoer2-ICD release	113
Glial interference: impact of type I interferon in neurodegenerative diseases	112
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy	108
AIF3 splicing switch triggers neurodegeneration	101
Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration	100
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders	99
Astrocytes of the optic nerve exhibit a region-specific and temporally distinct response to elevated intraocular pressure	95
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023	90
Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis	82
A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques	72
A partial Drp1 knockout improves autophagy flux independent of mitochondrial function	70

Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays	70
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	69
Alzheimer’s disease: targeting the peripheral circulation	69
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium	67
Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases	67
Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice	62
Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO	61
CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals	61
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	60
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease	58
The gut microbiome regulates astrocyte reaction to Aβ amyloidosis through microglial dependent and independent mechanisms	57
Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson’s disease	57
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	56
Positron emission tomography tracers for synucleinopathies	55
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	55
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	54
Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells	53
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	52
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (Part 1): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	50
Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination	50
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	50
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	48
Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer’s disease: an updated overview of nonpharmacological therapies	48